The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes.
 
Morgan Zenner
No Relationships to Disclose
 
Spencer Lessans
No Relationships to Disclose
 
Kai Rejeski
Honoraria - Celgene/Bristol-Myers Squibb; Kite/Gilead; Novartis
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb
Research Funding - Kite/Gilead
Travel, Accommodations, Expenses - Kite/Gilead; Pierre Fabre
 
Miguel-Angel Perales
Stock and Other Ownership Interests - NexImmune
Honoraria - MorphoSys
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Incyte; Kite, a Gilead Company; Medigene; Merck; NexImmune; Novartis; Pfizer
Research Funding - Incyte (Inst); Kite, a Gilead Company (Inst); Miltenyi Biotec (Inst); Nektar (Inst); Novartis (Inst)
 
Richard T. Maziarz
Leadership - Artiva
Honoraria - Novartis
Consulting or Advisory Role - incyte; Kite/Gilead; Novartis
Research Funding - Allovir; Bristol-Myers Squibb/Celgene/Juno; Gamida Cell; Novartis; ORCA Therapeutics
Patents, Royalties, Other Intellectual Property - ATHERSYS, INC shared patent re: use of mesenchymal stromal cells for treatment of GVHD
 
Andy I. Chen
Consulting or Advisory Role - Genentech; Kite, a Gilead Company
Research Funding - Asana Biosciences (Inst); Genentech/Roche (Inst); Novartis (Inst); Seagen (Inst)
 
David L. Porter
Employment - Genentech/Roche (I)
Stock and Other Ownership Interests - Genentech/Roche (I)
Honoraria - Novartis
Consulting or Advisory Role - Incyte; Janssen; Kite, a Gilead Company; Novartis
Research Funding - Novartis
 
Stephen J. Schuster
Consulting or Advisory Role - Acerta Pharma/AstraZeneca; BeiGene; Celgene; Genentech/Roche; Incyte; Janssen; Legend Biotech; Loxo; MorphoSys; MustangBio; Novartis; Regeneron
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); Celgene (Inst); DTRM (Inst); Genentech/Roche (Inst); Incyte (Inst); Juno Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent Combination Therapies of CAR and PD-1 Inhibitors (via University of Pennsylvania with royalties to Novartis)
 
Joseph McGuirk
Honoraria - AlloVir; Kite, a Gilead company; Magenta Therapeutics; Nektar; Sana Biotechnology
Consulting or Advisory Role - Allovir; crispr therapeutics; EcoR1 Capital; Juno Therapeutics; Kite, a Gilead company; Magenta Therapeutics
Speakers' Bureau - Kite/Gilead
Research Funding - AlloVir (Inst); Astellas Pharma (Inst); Bellicum Pharmaceuticals (Inst); Fresenius Biotech (Inst); Gamida Cell (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Novartis (Inst); Pluristem Therapeutics (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company; SITC/ACCC; Syncopation Life Sciences
 
Michael Russell Bishop
Honoraria - Bristol-Myers Squibb/Celgene/Juno; Incyte; Incyte; Sanofi/Aventis
Consulting or Advisory Role - Arcellx; Autolus; BMS; Chimeric Therapeutics; crispr therapeutics; In8Bio; Iovance Biotherapeutics; Johnson & Johnson/Janssen; Kite, a Gilead company; Novartis; Sana Biotechnology
Speakers' Bureau - Abbvie/Genmab; ADC Therapeutics; Bristol-Myers Squibb; Incyte; Kite, a Gilead company; Sanofi; SERVIER
Research Funding - Arcellx (Inst); crispr therapeutics (Inst); Iovance Biotherapeutics (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - BMS; Kite/Gilead; Novartis
 
Veronika Bachanova
Consulting or Advisory Role - Karyopharm Therapeutics; Kite, a Gilead Company; Seagen
Research Funding - Celgene (Inst); Incyte; Novartis (Inst)
 
Loretta J. Nastoupil
Honoraria - ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb; Caribou Biosciences; Daiichi Sankyo/UCB Japan; Epizyme; Genentech/Roche; Genmab; Gilead Sciences; Incyte; Ipsen; Janssen Oncology; Morphosys; Novartis; Takeda
Consulting or Advisory Role - Interius Biotherapeutics; SIRPant Immunotherapeutics
Research Funding - Allogene Therapeutics; Bristol-Myers Squibb/Celgene; Caribou Biosciences; Daiichi Sankyo/UCB Japan; Daiichi Sankyo/UCB Japan; Epizyme; Genentech/Roche; Genmab; Gilead Sciences; IgM Biosciences; Ipsen; Janssen Biotech; Novartis; Takeda
Travel, Accommodations, Expenses - Genentech/Roche
 
Peter A. Riedell
Honoraria - Novartis
Consulting or Advisory Role - Abbvie; ADC Therapeutics; BeiGene; Bristol-Myers Squibb/Celgene; CVS; Genentech/Roche; Genmab; Intellia Therapeutics; Kite, a Gilead company; Nektar; Novartis; Pharmacyclics/Janssen; Sana Biotechnology
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Calibr (Inst); Cellectis (Inst); crispr therapeutics (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Tessa Therapeutics (Inst); Xencor (Inst)
 
Olalekan O. Oluwole
Honoraria - Kite, a Gilead company
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Allogene Therapeutics; Autolus Therapeutics; CARGO Therapeutics; Caribou Biosciences; Epizyme; Gilead Sciences; Kite/Gilead; Nektar; Novartis; TG Therapeutics
Research Funding - Kite, a Gilead company (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Shakthi Bhaskar
No Relationships to Disclose
 
Vivek Patel
Honoraria - Primum
Consulting or Advisory Role - Ipsen